-- 根据周四提交给澳大利亚证券交易所的文件，Austral Resources Australia（ASX：AR1）表示，已完成Lady Loretta矿区的结算，并已根据交易条款从嘉能可（Glencore）收到4000万澳元。 该公司表示，约1440万澳元的款项已用于偿还预计的矿区修复保证金，Austral将承担后续的修复义务。 文件补充道，根据交易条款，Austral将向嘉能可支付Lady Loretta矿区所有氧化铜和硫化铜产量的2.5%净冶炼收益权使用费，并签署一份承购协议，承购该矿区所有铜产品。 文件还补充道，Lady Annie扩建项目（又称Annie Deeps）将于第三季度开始钻探，同时，为扩大公司矿石供应渠道而进行的战略性矿坑壁削减工程将于第二季度启动。 该公司补充说，和解所得现金将使澳斯特拉尔摆脱债务，从而增强其资产负债表。
Related Articles
Research
Research Alert: Xpo Q1 Earnings Beat As Margins Expand And Tonnage Turns Positive
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:XPO reported Q1 EPS of $1.01 vs. $0.73 a year ago, beating consensus by $0.13, while revenue of $2.1B grew 7% and beat estimates by $60M. Adjusted EBITDA surged 15% to $319M, demonstrating accelerating momentum across the business. We believe the combination of margin expansion, positive volume inflection, and strong cash generation supports XPO's trajectory toward accelerating free cash flow generation. North American LTL performance was solid, with adjusted operating ratio improving 200 bps to 83.9% and 20% growth in adjusted operating income. Critically, tonnage per day turned positive at +0.1% vs. Q4 2025's -4.5% decline, marking an inflection point and suggesting early demand stabilization signs. Yield growth excluding fuel remained robust at 4.0%, supported by service improvements and AI-driven network optimization, while cash from operations grew 29% to $183M. In our view, XPO's insourcing strategy and operational leverage position the company well for continued margin expansion and cash flow growth.
$XPO
Research
Research Alert: Cigna: Mcr Improvement Supports Q1 Eps Beat, Guidance Raise
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:CI reported Q1 2026 adjusted EPS of $7.79 (+16% Y/Y), beating the $7.61 consensus and prompting a $0.10 raise to annual EPS guidance. Total revenues rose 5% Y/Y to $68.5B, due to Evernorth Health Services' growth of 9% Y/Y to $58.4B, while Cigna Healthcare's revenues fell 21% Y/Y reflecting the Medicare business divestiture. The strong Evernorth performance, including 11% Y/Y growth in Pharmacy Benefit Services due to favorable drug mix and 6% Y/Y growth in Specialty and Care Services, supports the company's strategic pivot toward higher-margin services. Management maintained Medical Care Ratio guidance at 83.7%-84.7% for 2026, demonstrating continued cost discipline amid operational improvements. Operational efficiency improved with its SG&A expense ratio declining 100bps to 5.4%, while Cigna Healthcare pre-tax margins expanded 430bps to 13.2% and the Medical Care Ratio improved to 79.8% from 82.2%, primarily benefiting from the Medicare divestiture.
$CI
Research
JPMorgan Downgrades Kaiser Aluminum to Underweight From Neutral, Adjusts Price Target to $142 From $124
$KALU